Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia
Grace R, Bennett C, Ritchey A, Jeng M, Thornburg C, Lambert M, Neier M, Recht M, Kumar M, Blanchette V, Klaassen R, Buchanan G, Kurth M, Nugent D, Thompson A, Stine K, Kalish L, Neufeld E. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood & Cancer 2011, 58: 221-225. PMID: 21674758, PMCID: PMC3863944, DOI: 10.1002/pbc.23130.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsChildChild, PreschoolChronic DiseaseCohort StudiesFemaleFollow-Up StudiesGlucocorticoidsHumansImmunoglobulins, IntravenousImmunologic FactorsInfantInfant, NewbornLongitudinal StudiesMalePlatelet CountPrednisoneProspective StudiesRetrospective StudiesRituximabThrombocytopeniaTreatment OutcomeConceptsResponse to rituximabResponse to steroidsSecondary immune thrombocytopeniaChronic immune thrombocytopeniaImmune thrombocytopeniaPredictor of response to rituximabPediatric chronic immune thrombocytopeniaRefractory to other therapiesPositive response to steroidsPredictors of therapy responseTreated with rituximabWeeks of rituximabPediatric immune thrombocytopeniaDays of steroidsOverall response rateTreatment response dataLocal IRB approvalTherapy responseRituximabTreatment responseMultivariate predictorsIRB approvalMultivariate analysisTreatment choiceEvaluate univariate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply